Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 13;15(12):3172.
doi: 10.3390/cancers15123172.

Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions

Enrico Sammarco  1 , Fiorella Manfredi  1 , Amedeo Nuzzo  1 , Marco Ferrari  1 , Adele Bonato  1 , Alessia Salfi  1 , Debora Serafin  1 , Luca Zatteri  1 , Andrea Antonuzzo  2 , Luca Galli  1
Affiliations
Review

Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions

Enrico Sammarco et al. Cancers (Basel). .

Abstract

Immune checkpoint inhibitor-based therapies represent the current standard of care in the first-line treatment of advanced renal cell carcinoma. Despite a clear benefit in survival outcomes, a considerable proportion of patients experience disease progression; prospective data about second-line therapy after first-line treatment with immune checkpoint inhibitors are limited to small phase II studies. As with other solid tumors (such as melanoma and non-small cell lung cancer), preliminary data about the clinical efficacy of rechallenge of immunotherapy (alone or in combination with other drugs) in renal cell carcinoma are beginning to emerge. Nevertheless, the role of rechallenge in immunotherapy in this setting of disease remains unclear and cannot be considered a standard of care; currently some randomized trials are exploring this approach in patients with metastatic renal cell carcinoma. The aim of our review is to summarize main evidence available in the literature concerning immunotherapy rechallenge in renal carcinoma, especially focusing on biological rationale of resistance to immune checkpoint inhibitors, on the published data of clinical efficacy and on future perspectives.

Keywords: combination treatment; immune checkpoint inhibitors (ICIs); rechallenge; renal cell carcinoma (RCC); resistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Motzer R.J., Escudier B., George S., Hammers H.J., Srinivas S., Tykodi S.S., Sosman J.A., Plimack E.R., Procopio G., McDermott D.F., et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020;126:4156–4167. doi: 10.1002/cncr.33033. - DOI - PMC - PubMed
    1. Powles T., Plimack E.R., Soulières D., Waddell T., Stus V., Gafanov R., Nosov D., Pouliot F., Melichar B., Vynnychenko I., et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21:1563–1573. doi: 10.1016/S1470-2045(20)30436-8. - DOI - PubMed
    1. Motzer R., Alekseev B., Rha S.Y., Porta C., Eto M., Powles T., Grünwald V., Hutson T.E., Kopyltsov E., Méndez-Vidal M.J., et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N. Engl. J. Med. 2021;384:1289–1300. doi: 10.1056/NEJMoa2035716. - DOI - PubMed
    1. Motzer R.J., Powles T., Burotto M., Escudier B., Bourlon M.T., Shah A.Y., Suárez C., Hamzaj A., Porta C., Hocking C.M., et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): Long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23:888–898. doi: 10.1016/S1470-2045(22)00290-X. - DOI - PMC - PubMed
    1. Choueiri T.K., Motzer R.J., Rini B.I., Haanen J., Campbell M.T., Venugopal B., Kollmannsberger C., Gravis-Mescam G., Uemura M., Lee J.L., et al. Updated efficacy results from the JAVELIN Renal 101 trial: First-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann. Oncol. 2020;31:1030–1039. doi: 10.1016/j.annonc.2020.04.010. - DOI - PMC - PubMed